Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer�s disease (AD) because\r\ncholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia\r\ngravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine,\r\nand galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase\r\ninhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues.\r\nIn this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This\r\npharmacological approach continues to be active with many promising compounds.
Loading....